Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630808 · ClinicalTrials.gov registry record · Phase 3
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Nicox Ophthalmics.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
- 20
- Study locations
NCT04630808 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Nicox Ophthalmics. The registered enrollment target is 696 participants, above the 265-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (163% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT04630808, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Nicox Ophthalmics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Conditions Studied
Interventions
- DRUG NCX 470 0.1%
- DRUG Latanoprost 0.005%
Study Locations (20)
California
- Nicox Clinical Site - Burbank
- Nicox Clinical Site - Garden Grove
- Nicox Clinical Site - Huntington Beach
- Nicox Clinical Site - La Jolla
- Nicox Clinical Site - Murrieta
- Nicox Clinical Site - Newport Beach
- Nicox Clinical Site - Pasadena
- Nicox Clinical Site - Petaluma
- Nicox Clinical Site - Redlands
- Nicox Clinical Site - San Francisco
Florida
- Nicox Clinical Site - Boynton Beach
- Nicox Clinical Site - Delray Beach
- Nicox Clinical Site - Fort Lauderdale
- Nicox Clinical Site - Fort Myers
- Nicox Clinical Site - Jacksonville
- Nicox Clinical Site - Jupiter
Arizona
- Nicox Clinical Site - Chandler
- Nicox Clinical Site - Phoenix
Alabama
- Nicox Clinical Site - Dothan
Connecticut
- Nicox Clinical Site - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04630808
The ClinicalTrials.gov registry entry for NCT04630808 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 696 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 265-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (163% higher). The listed sponsor is Nicox Ophthalmics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which NCX 470 0.1% is the first listed.
NCT04630808 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04630808 about?
NCT04630808 is a clinical study titled "MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be admi...
What is the current status of trial NCT04630808?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2020-11-09. Estimated completion is 2025-06-25.
What conditions does trial NCT04630808 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT04630808?
The interventions under investigation include: NCX 470 0.1% (DRUG), Latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT04630808?
This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04630808 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.